Humedix Co

Humedix Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humedix Co (200670.KQ) as of Oct 20, 2026 is 42.33 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 44.97 B KRW — a change of -5.86% (lower).

EBITDA

42.33 BKRW

YoY

-5.86%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humedix Co is 2025 42.33 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humedix Co was 2024 44.97 B KRW. It decreases by -5.86% lower compared to the previous year.

The Humedix Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
11.09 B KRW
Jan 1, 2019
13.09 B KRW
Jan 1, 2020
17.87 B KRW
Jan 1, 2021
15.45 B KRW
Jan 1, 2022
35.50 B KRW
Jan 1, 2023
39.01 B KRW
Jan 1, 2024
44.97 B KRW
Jan 1, 2025
42.33 B KRW
The Humedix Co EBITDA history
YEAREBITDAYoY
42.33 BKRW-5.86%
44.97 BKRW+15.26%
39.01 BKRW+9.89%
35.50 BKRW+129.72%
15.45 BKRW-13.49%
17.87 BKRW+36.49%
13.09 BKRW+18.07%
11.09 BKRW-12.80%
12.71 BKRW+10.47%
11.51 BKRW-18.84%
14.18 BKRW+75.68%
8.07 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humedix Co Stock analysis

What does Humedix Co do? Humedix Co Ltd, identified by the ticker symbol 200670.KQ and ISIN KR7200670008, is a South Korean enterprise operating within the health care sector, specifically in the pharmaceuticals industry. Headquartered in Seongnam, the company has established itself as a specialized manufacturer and distributor of medical devices and therapeutic products. The firm's core business activities revolve around the production and sale of hyaluronic acid-based medical devices, which are widely utilized in various clinical applications, as well as specialized products designed for the treatment of arthritis. This focus on hyaluronic acid highlights the company's commitment to addressing significant health challenges related to joint health and mobility, catering to a growing demographic concerned with degenerative joint conditions. The company maintains a workforce of 338 full-time employees, reflecting its operational scale and capacity to manage both domestic and international supply chains. Humedix achieved a significant milestone in its corporate history by conducting its initial public offering on December 26, 2014. This event marked the company's entry into the public markets, providing it with increased visibility and access to capital for potential expansion and research initiatives. Since its public listing, Humedix has continued to refine its product portfolio and strengthen its market presence. Geographically, the company distributes its products not only within the domestic South Korean market but also extends its reach to overseas markets. This dual-market strategy allows Humedix to diversify its revenue streams and mitigate risks associated with regional economic fluctuations. By serving both local and international customers, the company leverages its manufacturing capabilities to meet diverse regulatory and consumer demands across different regions. The headquarters in Seongnam serves as the central hub for its administrative, research, and distribution operations, ensuring efficient coordination of its business activities. Through its dedicated efforts in developing hyaluronic acid-based solutions, Humedix Co Ltd continues to play a role in the broader health care ecosystem, providing essential medical devices and treatments that improve patient outcomes. The company's website, http://www.humedix.com/, serves as a primary resource for stakeholders seeking further information about its products, corporate governance, and financial performance. As the health care landscape evolves, Humedix remains focused on its core competencies in pharmaceutical manufacturing and medical device distribution, aiming to sustain growth and innovation in its specialized field. Humedix Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humedix Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humedix Co is 42.33 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Humedix Co changed from 44.97 B KRW to 42.33 B KRW, representing a -5.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Humedix Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Humedix Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Humedix Co

All Key Metrics — Humedix Co